Apex Biotechnology Corp (1733) — Cash Flow-to-Debt Ratio
Apex Biotechnology Corp (1733) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of NT$5.19 Million could theoretically repay 0% of its total liabilities (NT$494.69 Million) in one year. Explore Apex Biotechnology Corp (1733) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Apex Biotechnology Corp Cash Flow-to-Debt Ratio (2002–2024)
Historical debt coverage capacity for Apex Biotechnology Corp across 23 annual periods. Also explore Apex Biotechnology Corp balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Apex Biotechnology Corp (2002–2024)
Year-by-year debt coverage analysis for Apex Biotechnology Corp. For market capitalisation and broader financial context, see 1733 market cap.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.55x | NT$328.67 Million | NT$595.70 Million | ▲ +19.8% |
| 2023 | 0.46x | NT$230.39 Million | NT$500.07 Million | ▲ +1106.2% |
| 2022 | 0.04x | NT$26.62 Million | NT$696.81 Million | ▼ -80.5% |
| 2021 | 0.20x | NT$179.87 Million | NT$916.91 Million | ▼ -29.7% |
| 2020 | 0.28x | NT$280.60 Million | NT$1.01 Billion | ▼ -31.4% |
| 2019 | 0.41x | NT$462.52 Million | NT$1.14 Billion | ▲ +442.7% |
| 2018 | 0.07x | NT$67.57 Million | NT$901.70 Million | ▲ +9.5% |
| 2017 | 0.07x | NT$70.83 Million | NT$1.03 Billion | ▼ -82.4% |
| 2016 | 0.39x | NT$298.06 Million | NT$768.49 Million | ▼ -37.2% |
| 2015 | 0.62x | NT$472.15 Million | NT$764.69 Million | ▲ +79.6% |
| 2014 | 0.34x | NT$267.60 Million | NT$778.52 Million | ▼ -43.0% |
| 2013 | 0.60x | NT$484.77 Million | NT$803.47 Million | ▼ -13.0% |
| 2012 | 0.69x | NT$509.67 Million | NT$735.18 Million | ▼ -1.4% |
| 2011 | 0.70x | NT$273.45 Million | NT$388.76 Million | ▼ -51.6% |
| 2010 | 1.45x | NT$465.59 Million | NT$320.60 Million | ▲ +12.6% |
| 2009 | 1.29x | NT$391.29 Million | NT$303.31 Million | ▼ -4.9% |
| 2008 | 1.36x | NT$299.96 Million | NT$221.21 Million | ▼ -23.8% |
| 2007 | 1.78x | NT$364.62 Million | NT$204.80 Million | ▼ -4.2% |
| 2006 | 1.86x | NT$363.71 Million | NT$195.73 Million | ▲ +95.7% |
| 2005 | 0.95x | NT$212.14 Million | NT$223.36 Million | ▼ -44.1% |
| 2004 | 1.70x | NT$218.54 Million | NT$128.64 Million | ▼ -31.4% |
| 2003 | 2.48x | NT$302.25 Million | NT$122.00 Million | ▲ +178.0% |
| 2002 | 0.89x | NT$79.49 Million | NT$89.21 Million | — |